About C-Squared Pharma India Private Limited
Data last updated: 07 March 2026
C-Squared Pharma India Private Limited is a foreign private limited company based in Mumbai, Maharashtra, India, a subsidiary of C-Squared Pharma S.A.R.L. It specialises in real estate brokerage and services, a part of the broader real estate and construction sector. Incorporated on 09 April 2019, the company has been in operation for over 7 years.
Registered with ROC Mumbai under CIN U74999MH2019FTC323867.
Capital: an authorised share capital of ₹65 Lakh and a paid-up capital of ₹39 Lakh. It is led by directors Andrew Ramsey Badrot and Ragavendran Vasudevan.
Last AGM: 12 September 2025. Financial statements filed for year ended 31 March 2025. Office: 5Th Floor Raaj Chamber New Nagardas Road Andheri East, Mumbai, Maharashtra, India – 400069.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.51 Cr, a growth of 56% compared to the previous year.
It operates as a subsidiary of C-Squared Pharma S.A.R.L.
The company is associated with 1 brand - C2 Pharma.
For more details, the company can be reached via its website c2pharma.com.
-
Email*****@*****.com
-
Telephone**************
-
Website
-
Social Media**************
-
Registered Address5Th Floor Raaj Chamber New Nagardas Road Andheri East, Mumbai, Maharashtra, India – 400069
-
IndustryReal Estate and Construction, Real Estate Brokerage & Services
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with C-Squared Pharma India Private Limited
C-Squared Pharma India Private Limited operates one associated brand: C2 Pharma. These brands represent C-Squared Pharma India Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufactures and distributes active pharmaceutical ingredients and compounds worldwide. | c2pharma.com |
Competitors & Alternatives of C-Squared Pharma India Private Limited
Brands and companies operating in the same space as C-Squared Pharma India Private Limited include AnalytiCon Discovery, BJ Biochem, Magellan BioScience Group and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
AnalytiCon Discovery
|
Natural products chemistry is specialized in by AnalytiCon Discovery. | Potsdam, Germany, Germany | 2000 |
BJ Biochem
|
Research and development services for sugar derivatives are provided. | Cheongju-si, South Korea, South Korea | 2016 |
Magellan BioScience Group
|
Identifies and develops microbial natural product leads for pharmaceutical and industrial applications | Tampa, United States, United States | 1997 |
Bicoll
|
Preclinical services for drug discovery from natural products are provided. | Munich, Germany, Germany | 2000 |
Venomtech
|
Venom research solutions are supplied for bioprospecting and biological studies. | Sandwich, United Kingdom, United Kingdom | 2010 |
Synaco Group
|
Produces and markets natural flavours and a neurotransmitter inhibitor (ATA Mg) | Alleur, Belgium, Belgium | 1999 |
Celtarys
|
Company that develops and commercializes novel fluorescent probes and ligands for fluorescence-based methods in drug discovery | Spain | 2021 |
Greenspirit
|
Regulatory consulting services are offered to pharmaceutical and nutraceutical manufacturers. | Barcelona, Spain, Spain | 2008 |
Metagreen
|
Develops technologies to harness compounds from natural production. | Los Angeles, United States, United States | 2015 |
Business Activity of C-Squared Pharma India Private Limited
C-Squared Pharma India Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of C-Squared Pharma India Private Limited
C-Squared Pharma India Private Limited is audited by MONIL GALA & ASSOCIATES for the financial year 2021. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| MONIL GALA & ASSOCIATES | blur-value | blur-value | blur-value |
Board of Directors of C-Squared Pharma India Private Limited
C-Squared Pharma India Private Limited is currently managed by 2 directors, with 2 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Andrew Ramsey Badrot | Director | 09 Apr 2019 | 7 Years 3 Months | Current |
| Ragavendran Vasudevan | Director | 05 Apr 2023 | 3 Years 3 Months | Current |
Financials of C-Squared Pharma India Private Limited FY 2025 filings available
C-Squared Pharma India Private Limited reported revenue of ₹1.51 Cr (up 56% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of C-Squared Pharma India Private Limited
As of FY 2021, C-Squared Pharma India Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings C-Squared Pharma India Private Limited
C-Squared Pharma India Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at C-Squared Pharma India Private Limited
View historical data on people associated with C-Squared Pharma India Private Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of C-Squared Pharma India Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of C-Squared Pharma India Private Limited
GSTIN & GST Filing Data of C-Squared Pharma India Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for C-Squared Pharma India Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of C-Squared Pharma India Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by C-Squared Pharma India Private Limited
MSME Payment Delays by C-Squared Pharma India Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of C-Squared Pharma India Private Limited
Subsidiaries & Group Companies of C-Squared Pharma India Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of C-Squared Pharma India Private Limited with ownership details.
MCA Filings & Documents of C-Squared Pharma India Private Limited
MCA Filings & Documents of C-Squared Pharma India Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on C-Squared Pharma India Private Limited
Recent News on C-Squared Pharma India Private Limited
Frequently Asked Questions about C-Squared Pharma India Private Limited
C-Squared Pharma India Private Limited is an active foreign private limited company in the real estate and construction sector based in Mumbai, Maharashtra, India. It was incorporated on 09 April 2019 (7+ years old) and is registered under CIN U74999MH2019FTC323867.
C-Squared Pharma India Private Limited reported revenue of ₹1.51 Cr for FY 2025 (up 56.00% YoY).
The current directors of C-Squared Pharma India Private Limited are:
The primary industry of C-Squared Pharma India Private Limited is real estate and construction. The company specifically operates in real estate brokerage and services. The company is currently active in this sector.
C-Squared Pharma India Private Limited can be reached at the registered office: 5Th Floor Raaj Chamber New Nagardas Road Andheri East, Mumbai, Maharashtra, India – 400069, or through the website c2pharma.com.
The authorised capital is ₹65 Lakh, and the paid-up capital is ₹39 Lakh.